COVID-19 vaccine effectiveness against SARS-CoV-2-confirmed hospitalisation in the eastern part of the WHO European Region (2022-2023): a test-negative case-control study from the EuroSAVE network.

ABSTRACT:

Background

Understanding COVID-19 vaccine effectiveness (VE) in preventing severe disease is critical to inform vaccine policy. We used the test-negative design to estimate VE against SARS-CoV-2-confirmed hospitalisation in adults ≥18 years in the eastern WHO European Region.

Methods

We included patients hospitalised for severe acute respiratory infection (SARI) at sentinel surveillance sites in Albania, Georgia, Kyrgyzstan, North Macedonia, Serbia, and in Kosovo. We collected demographic information, COVID-19 vaccination history, and tested respiratory samples for SARS-CoV-2 by RT-PCR. We calculated VE of any vaccine dose received within 12 months (Annual VE) as [(1 - adjusted Odds Ratio) x 100%] using a one-stage pooled analysis. The reference group included unvaccinated i

SUBMITTER: Katz MA 

PROVIDER: S-EPMC11670677 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature